SCHEMBL14073364

SCHEMBL14073364

CCOc1ccccc1NC(=O)N1CCCN(c2nc3cc(F)c(C)cc3cc2C#N)CC1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 8/20 0.70
▸ KDM4E B2RXH2 8/20 0.70
▸ MEN1 O00255 4/20 0.70
▸ KMT2A Q03164 4/20 0.70
▸ SMN1; SMN2 Q16637 4/20 0.70
▸ CASP1 P29466 4/20 0.70
▸ LMNA P02545 3/20 0.70
▸ TSHR P16473 3/20 0.70
▸ CASP7 P55210 3/20 0.70
▸ MAPK1 P28482 1/20 0.70
▸ ATM Q13315 1/20 0.70
▸ TDP1 Q9NUW8 1/20 0.70
▸ P2RY12 Q9H244 8/20 0.55
▸ MAPT P10636 3/20 0.51
▸ HPGD P15428 3/20 0.51
▸ HSD17B10 Q99714 3/20 0.51
▸ USP2 O75604 1/20 0.51
▸ ALOX15 P16050 1/20 0.51
▸ HTT P42858 1/20 0.51
▸ L3MBTL1 Q9Y468 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12043100 0.95 MEN1 (0.69) ALDH1A1KDM4EMEN1KMT2ASMN1; SMN2
SCHEMBL12043094 0.87 KDM4E (0.85) ALDH1A1KDM4EMEN1KMT2ASMN1; SMN2
SCHEMBL19495014 0.86 KDM4E (0.58) ALDH1A1KDM4EMEN1KMT2ASMN1; SMN2
SCHEMBL14073362 0.85 KDM4E (0.70) ALDH1A1KDM4EMEN1KMT2ASMN1; SMN2
SCHEMBL12043197 0.84 KDM4E (0.64) ALDH1A1KDM4EMEN1KMT2ASMN1; SMN2
SCHEMBL2525573 0.83 KDM4E (0.84) ALDH1A1KDM4EMEN1KMT2ASMN1; SMN2
SCHEMBL19495358 0.79 MEN1 (0.54) ALDH1A1KDM4EMEN1KMT2ASMN1; SMN2
SCHEMBL16940595 0.79 KDM4E (0.74) ALDH1A1KDM4EMEN1KMT2ASMN1; SMN2
SCHEMBL12043096 0.78 MEN1 (0.81) ALDH1A1KDM4EMEN1KMT2ASMN1; SMN2
SCHEMBL14073368 0.78 KDM4E (0.64) ALDH1A1KDM4EMEN1KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080234253-A1 Methods and Compositons for Stimulating Neurogenesis and Inhibiting Neuronal Degeneration NEURONASCENT, INC. (US) 2008-09-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080234253-A1 Methods and Compositons for Stimulating Neurogenesis and Inhibiting Neuronal Degeneration DCX, BDNF, GAP43 ALDH1A1 1544/4885KDM4E 4443/4885MEN1 1487/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback